Apta-1 has in the ongoing toxicology program indicated a good safety profile that resulted in a greater substance need, which delays the program
2018-08-29
Aptahem AB (publ) announce today that the company’s ongoing pre-clinical toxicology development program is delayed pending the manufacturing of more Apta-1. The drug candidate Apta-1 has in the company’s ongoing toxicology program indicated a good safety profile, which has...
Read More